Janux Therapeutics, Inc.
JANXHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive. The $1.23B market capitalization puts JANX squarely in small-cap range for its industry. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Market Cap
$1.23B
Beta
2.52
P/E (TTM)
—
P/E (Fwd)
-7.64
EPS (TTM)
$-1.64
EPS (Fwd)
$-2.62
ROE
-10.7%
ROA
-8.8%
Cash
$970.9M
Total Debt
$21.0M
Free CF
-$16.4M
52W Change
-16.7%
Annual Financials
Cash vs Debt
Where JANX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, JANX finished 32.75% above its 150-day moving average ($14.84) and 25.72% above its 200-day moving average ($15.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JANX overbought or oversold?
At the September 3, 2026 close, JANX's RSI(14) was 81.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $970.9M in cash and $21.0M in debt, JANX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$16.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -10.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $8.6M to $10.0M.
Janux Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, JANX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing JANX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.